anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Feline mammary carcinoma (FMC) is a common aggressive and highly metastatic cancer affecting female cats. Early detection is essential for preventing local and distant metastasis, thereby improving overall survival rates. While acquiring molecular data before surgery offers significant potential benefits, the current protein biomarkers for monitoring disease progression in non-metastatic FMC (NmFMC) and metastatic FMC (mFMC) are limited. The objective of this study was to investigate the serum peptidome profiles of NmFMC and mFMC using liquid chromatography-tandem mass spectrometry. A cross-sectional study was conducted to compare serum peptidome profiles in 13 NmFMC, 23 mFMC and 18 healthy cats. The liquid chromatography-tandem mass spectrometry analysis was performed on non-trypsinized samples.
RESULTS: Out of a total of 8284 expressed proteins observed, several proteins were found to be associated with human breast cancer. In NmFMC, distinctive protein expressions encompassed double-stranded RNA-binding protein Staufen homolog 2 (STAU2), associated with cell proliferation, along with bromodomain adjacent to zinc finger domain 2A (BAZ2A) and gamma-aminobutyric acid type A receptor subunit epsilon (GABRE), identified as potential treatment targets. Paradoxically, positive prognostic markers emerged, such as complement C1q like 3 (C1QL3) and erythrocyte membrane protein band 4.1 (EPB41 or 4.1R). Within the mFMC group, overexpressed proteins associated with poor prognosis were exhibited, including B-cell lymphoma 6 transcription repressor (BCL6), thioredoxin reductase 3 (TXNRD3) and ceruloplasmin (CP). Meanwhile, the presence of POU class 5 homeobox (POU5F1 or OCT4) and laminin subunit alpha 1 (LAMA1), reported as metastatic biomarkers, was noted.
CONCLUSION: The presence of both pro- and anti-proliferative proteins was observed, potentially indicating a distinctive characteristic of NmFMC. Conversely, proteins associated with poor prognosis and metastasis were noted in the mFMC group.
The present invention relates to a Chinese medicine sitting bathing preparation for treating chronic prostatitis, a preparation method and use. The present invention belongs to the technical field of the prepared Chinese herbal medicine. The Chinese medicine sitting bathing preparation for treating chronic prostatitis is prepared from dandelion, patrinia, plantain herb, stir-baked squama manitis, red sage root, hypoglaucous collett yam rhizome, thunberg fritillary bulb, jiuxiang bug, tuber onion seed, combined spicebush root, milkvetch root, grassleaf sweetflag rhizome, thinleaf milkwort root and largetrifoliolious bugbane rhizome. The present invention has the preparation method: the medicines are uniformly mixed according to weight ratio and are pulverized into 80 meshes of coarse powder; then, the coarse powder is pulverized and processed into 1 to 100 micrometers of submicron powder, and finally, the submicron powder is respectively placed into a bag with the weight of 10 grams for standby. The present invention has the following application method: 10 grams of the product is placed into a cup and is stewed and soaked for 10 minutes with scalding boiled water; then, the product is poured into a sitting bath and is mixed with1500 milliliters of warm purified water at the temperature of 30 to 50 DEG C; the sitting bathing is carried out for 20 to 30 minutes, and the sitting bathing is carried out for one time to two times per day. The Chinese medicine sitting bathing preparation of the present invention is prepared aiming at the chronic prostatitis pathology. The present invention has the efficiency of clearing away heat and promoting diuresis, detoxicating, stimulating circulation to end stasis, resolving phlegm, discharging blood clots and tonifying the liver and kidney.
The H1 Implant is a cementless, ceramic hip resurfacing arthroplasty (HRA) device. The intended purpose of the H1 Implant is to provide an artificial substitute for a disease-damaged hip joint to replace the articulating surfaces of the hip while preserving the underlying femoral head and natural femoral neck. This is standard for a resurfacing hip prosthesis. This study will randomise patients to receive either The H1 Implant or a primary cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement (THR). Composite clinical success (CCS) scores, physical activity levels and patient reported outcome measures (PROMs) will be compared for the two groups. The primary objective of the study is to determine whether the H1 Implant is non-inferior to cementless THR in terms of CCS. The key secondary objective is to determine whether the H1 Implant is superior compared to cementless THR in terms of physical activity and PROMs. Other secondary objectives are to compare the H1 Implant and THR with respect to: safety, through collection of all device-related, operative site-related and systemic adverse events; and noise generation, through patient survey.
The Pilates technique consists of a series of low-impact exercises that build strength and flexibility throughout the body. All exercises performed 3 days in a week, 3 visits per week total of 9 sessions. In first week participants will perform 1 set of each exercise with 10 repetitions. In second week 2 sets of each exercise with 12 repetitions and in the third week both groups will perform 3 sets of each exercise with 15 repetitions with a rest interval of 2-3 minutes between sets.
BACKGROUND & AIMS: Infections by multidrug-resistant bacteria (MDRB) are an increasing healthcare problem worldwide. This study analyzes the incidence, burden, and risk factors associated with MDRB infections after liver transplant(ation) (LT).
METHODS: This retrospective, multicenter cohort study included adult patients who underwent LT between January 2017 and January 2020. Risk factors related to pre-LT disease, surgical procedure, and postoperative stay were analyzed. Multivariate logistic regression analysis was performed to identify independent predictors of MDRB infections within the first 90 days after LT.
RESULTS: We included 1,045 LT procedures (960 patients) performed at nine centers across Spain. The mean age of our cohort was 56.8 ± 9.3 years; 75.4% (n = 782) were male. Alcohol-related liver disease was the most prevalent underlying etiology (43.2.%, n = 451). Bacterial infections occurred in 432 patients (41.3%) who presented with a total of 679 episodes of infection (respiratory infections, 19.3%; urinary tract infections, 18.5%; bacteremia, 13.2% and cholangitis 11%, among others). MDRB were isolated in 227 LT cases (21.7%) (348 episodes). Enterococcus faecium (22.1%), Escherichia coli (18.4%), and Pseudomonas aeruginosa (15.2%) were the most frequently isolated microorganisms. In multivariate analysis, previous intensive care unit admission (0-3 months before LT), previous MDRB infections (0-3 months before LT), and an increasing number of packed red blood cell units transfused during surgery were identified as independent predictors of MDRB infections. Mortality at 30, 90, 180, and 365 days was significantly higher in patients with MDRB isolates.
CONCLUSION: MDRB infections are highly prevalent after LT and have a significant impact on prognosis. Enterococcus faecium is the most frequently isolated multi-resistant microorganism. New pharmacological and surveillance strategies aimed at preventing MDRB infections after LT should be considered for patients with risk factors.
IMPACT AND IMPLICATIONS: Multidrug-resistant bacterial infections have a deep impact on morbidity and mortality after liver transplantation. Strategies aimed at improving prophylaxis, early identification, and empirical treatment are paramount. Our study unveiled the prevalence and main risk factors associated with these infections, and demonstrated that gram-positive bacteria, particularly Enterococcus faecium, are frequent in this clinical scenario. These findings provide valuable insights for the development of prophylactic and empirical antibiotic treatment protocols after liver transplantation.
PURPOSE: A pharmaceutical composition containing L1CAM-specific anti-L1CAM antibody or antigen binding fragment of the antibody is provided to induce apoptosis of gallbladder carcinoma. CONSTITUTION: A pharmaceutical composition for suppressing growth or metastasis of gallbladder carcinoma contains anti-L1CMA antibody which specifically binds to L1CMA(L1 cell adhesion molecule) or an antigen binding fragment thereof. The anti-L1CMA antibody or fragment recognizes membrane-binding form or membrane-separated form. The antibody is A10-A3 antibody, Ab4, humanized antibody, human antibody, or UJ127. The pharmaceutical composition contains an oligonucleotide which suppresses L1CAM expression. The oligonucleotide is an antisense oligonucleotide, siRNA, or shRNA.
Aging causes numerous age-related diseases, leading the human species to death. Nevertheless, rejuvenating strategies based on cell epigenetic modifications are a possible approach to counteract disease progression while getting old. Cell reprogramming of adult somatic cells toward pluripotency ought to be a promising tool for age-related diseases. However, researchers do not have control over this process as cells lose their fate, and cause potential cancerous cells or unexpected cell phenotypes. Direct and partial reprogramming were introduced in recent years with distinctive applications. Although direct reprogramming makes cells lose their identity, it has various applications in regeneration medicine. Temporary and regulated in vivo overexpression of Yamanaka factors has been shown in several experimental contexts to be achievable and is used to rejuvenate mice models. This regeneration can be accomplished by altering the epigenetic adult cell signature to the signature of a younger cell. The greatest advantage of partial reprogramming is that this method does not allow cells to lose their identity when they are resetting their epigenetic clock. It is a regimen of short-term Oct3/4, Sox2, Klf4, and c-Myc expression in vivo that prevents full reprogramming to the pluripotent state and avoids both tumorigenesis and the presence of unwanted undifferentiated cells. We know that many neurological age-related diseases, such as Alzheimer's disease, stroke, dementia, and Parkinson's disease, are the main cause of death in the last decades of life. Therefore, scientists have a special tendency regarding neuroregeneration methods to increase human life expectancy.
This group will receive a low, medium or high dose of the H3N2 M2SR monovalent influenza vaccine administered intranasally. It will be compared with placebo in a 3:1 ratio.
BACKGROUND: IgA nephropathy is a renal lesion in patients with end-stage liver disease, called hepatic IgA nephropathy. The common manifestation of hepatic IgA nephropathy is microscopic hematuria. Sirolimus, often used to prevent organ rejection, has been reported to induce proteinuria after organ transplantation. But few cases of nephrotic proteinuria and hematuria are reported.
CASE PRESENTATION: In this case, a 45-year-old male with a long history of hepatic B virus infection and liver cirrhosis, received liver transplant and was taking sirolimus as one of his immunosuppression drugs. Overt proteinuria and hematuria occurred. With no proteinuria history before, renal biopsy was performed, which indicated IgA nephropathy.
CONCLUSION: We reported a liver recipient, who was taking sirolimus, developing nephrotic proteinuria and hematuria with IgA nephropathy. Further studies need to be carried out to disclose mechanism behind this phenomenon.
Disclosed are personal care compositions, including compositions for oral, throat and skin care comprising a blend of naturally occurring flavor or perfume ingredients or essential oils containing such ingredients, wherein the blend provides excellent antimicrobial activity and comprises at least two components, a first acyclic component selected from citral, neral, geranial, geraniol and nerol and a second cyclic-containing component selected from eucalyptol, carvacrol and eugeno.l. Preferably, the blend comprises 3, 4, 5 or more of the above components. Greater synergy in terms of antimicrobial efficacy may be obtained the more different components are blended together. The present compositions are effective in killing, suppressing the growth of and/or altering metabolism of microorganisms including those which cause undesirable oral cavity conditions including plaque, caries, calculus, gingivitis, periodontal disease and breath malodor. Optionally the blend further comprises additional antimicrobial and/or anti-inflammatory components, preferably naturally-occurring as well. The blend may also be used as a respiratory composition.
Participants ingested 6ml - 21ml (based on participants' weight) of clear, sugar-less liquid placebo mixed with 1/2 cup milk twice daily (once immediately after breakfast and once immediately after dinner). The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a glycerol-based placebo matched for color, texture, and taste to the active supplement.
PURPOSE: Periostin for inducing movement of nerve stem cells is provided to prevent and treat brain diseases and nervous diseases. CONSTITUTION: A kit for treating cancer contains periostin, cells which secrete periostin, and nerve cells which express suicide gene or anti-oncogene. The kit further contains an anticancer precursor which is converted to anticancer materials by the suicide gene. Periostin has an amino acid sequence of sequence number 1-4. The suicide gene is HSV-TK(herpes simplex virus-thymidine kinase) or cytosine deaminase. The anti-oncogene is PEX, Trail, or IFN-beta. A composition for preventing and treating neural disease or brain diseases contains periostin or the cells or neural stem cells secreting periostin.
The CBT-I is a weekly, 2-hour, 8 session, group-based program. CBT-I includes 4 central components: stimulus control, sleep restriction, relaxation training and cognitive therapy. The aim of CBT-I is to reduce sleep-related physiologic and cognitive arousal so that restorative sleep function can be re-established.
The system for automatically dispensing medications or other medical elements includes several groupings, i.e. vaults, of storage members, each vault containing approximately 100 individual cartridges, which each contains packages of unit-of-use doses of a given medication or other medical supply, such as syringes. Each storage member includes an ejector which ejects selected medications/supplies to a supply trough. The packages in the trough are moved to a central collator, which dispenses them to a bin receptacle which has been moved underneath the collator and which is typically identified with a particular patient. Information concerning medications/supplies for a particular patient is stored in a system database and used to determine the particular medications/supplies dispensed into the given bin. Bar coding is used to maintain control over the bins, and the medications, forming a closed information/control system. Particular medications and/or supplies which are not available in the automatic dispensing system are supplied from a supplemental medications cart which has been previously stocked with the correct additional medications by virtue of information from a control computer. The filled bins are transferred to a medication cart which can only be accessed as a result of a command signal after a particular patient and his/her associated bin have been matched. A nurse, having access to the correct bin and sector thereof, removes the medications from the cart and administers them to the patient.
All patients with a suspicion of non-ST-elevation acute coronary syndrome (NSTE-ACS) in the pre-hospital phase are eligible for inclusion. In all included patients, the POC cTn will be performed and the HEART-score will be calculated in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of both the POC cTn or the pre-hospital HEART-score will be blinded for the physicians at the emergency department (ED) and will not affect current treatment strategy. All patients with suspected NSTE-ACS will undergo hs-cTn testing and the HEART-score will also be calculated at the ED (T1, standard of care). Here, an additional venous blood sample will be drawn next to routine blood testing testing (T1).
A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and/or albumin and/or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters. These methods of isolating the hepatic progenitors are applicable to any vertebrates including human. The hepatic progenitor cell population is expected to be useful for cell therapies, for bioartificial livers, for gene therapies, for vaccine development, and for myriad toxicological, pharmacological, and pharmaceutical programs and investigations.
The acexamic acid zinc is used for manufacturing a composition for treating inflammatory bowel disease. ACTIVITY : Antiinflammatory; Antiulcer; Gastrointestinal-Gen. A male Wistar albino rat model of inflammatory bowel disease was used for evaluating the effect of acexamic acid zinc. The animal was administered orally with acexamic acid zinc (2.100 mg/kg) for 2 weeks and rectally administered as enema for 1 week (20 mg/ml). The animal was then cut and the colon was removed to measure the size of ulcer formed. The result showed that the acexamic acid zinc had effect of recovering intestinal tract inflammation by both oral and rectal administration. MECHANISM OF ACTION : None given.
BACKGROUND: Dietary interventions are crucial in modulating inflammation in humans. Strawberries are enjoyed by people of different ages as a result of their attractive phenotype and taste. In addition, the active compounds in strawberries may contribute to the reduction of inflammation. When developing new strawberry cultivars to address agricultural and environmental threats, the bioactivity of strawberries must be improved to maintain their health benefits.
RESULTS: We determined the phytochemical contents of extracts from a new Korean strawberry cultivar, with the CN7 cultivar extract possessing the highest total polyphenol and flavonoid contents compared to the CN5 and Seolhyang cultivar extracts. The new Korean strawberry cultivars reduced the expression of inflammatory-related genes in lipopolysaccharide (LPS)-induced RAW264.7 cells via the nuclear factor-kappa B signaling pathway, indicating an anti-inflammatory effect. The CN7 cultivar showed greater bioactivity potential and the highest ellagic acid content; hence, we assessed the effect of the CN7 cultivar in an LPS-stimulated mouse model. The CN7 cultivar treatment demonstrated its effectiveness in reducing inflammation via the downregulation of inflammatory cytokines secretion and gene expression.
CONCLUSION: The results obtained in the present study have revealed the observable differences of the newly developed strawberry cultivars with Seolhyang in mitigating inflammation induced by LPS. The enhanced phytochemical content of the CN7 cultivar extract may contribute to its improved anti-inflammatory effect. Therefore, it is crucial to maintain the nutritive benefits of strawberry during the development of new cultivation. © 2023 Society of Chemical Industry.
All participant will eat 6 meals of tuna fish. All participants will take a prebiotic dietary supplement.
PURPOSE: Rectal cancer and its treatment have a negative impact on health-related quality of life (HRQoL). If risk factors for sustained low HRQoL could be identified early, ideally before the start of treatment, individualised interventions could be identified and implemented to maintain or improve HRQoL. The study aimed to develop a multivariable prediction model for global HRQoL 12 months after rectal cancer treatment.
METHODS: Within COLOR II, a randomised, multicentre, international trial of laparoscopic and open surgery for rectal cancer, a sub-study on HRQoL included 385 patients in 12 hospitals and five countries. The HRQoL study was optional for hospitals in the COLOR II trial. EORTC QLQ-C30 and EORTC QLQ-CR38 were analysed preoperatively and at 1 and 12 months postoperatively. In exploratory analyses, correlations between age, sex, fatigue, pain, ASA classification, complications, and symptoms after surgery to HRQoL were studied. Bivariate initial analyses were followed by multivariate regression models.
RESULTS: Patient characteristics and clinical factors explained 4-10% of the variation in global HRQoL. The patient-reported outcomes from EORTC QLQ-C30 explained 55-65% of the variation in global HRQoL. The predominant predictors were fatigue and pain, which significantly impacted global HRQoL at all time points measured.
CONCLUSION: We found that fatigue and pain were two significant factors associated with posttreatment global HRQoL in patients treated for rectal cancer T1-T3 Nx. Interventions to reduce fatigue and pain could enhance global HRQoL after rectal cancer treatment.
TRIAL REGISTRATION: This trial is registered with ClinicalTrials.gov No. NCT00297791.
The control group receives two cycles of inducation chemotherapy consisting of standard DA 3+7 regimen without venetoclax. After CR/CRi achieved, subjects proceed allo-transplantation or consolidation therapy according to their ELN risks. The consolidation chemotherapy regimen consists of three cycles of intermediate （for age\>55 years）or high（for age≤ 55 years） dose cytarabine without venetoclax.
Participants received placebo i.v. infusion on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks plus SOC regimen.
* Patients should be instructed to notify their health care providers of any change in over-the-counter, prescription and supplement use. The health care provider should assess the patients’ medication history including all over-the-counter, prescription and herbal/natural preparations for those that may affect the pharmacodynamics or kinetics of propafenone hydrochloride [see Warnings and Precautions (5.4)]. 
  * Patients should also check with their health care providers prior to taking a new over-the-counter medicine. 
  * If patients experience symptoms that may be associated with altered electrolyte balance, such as excessive or prolonged diarrhea, sweating, vomiting, or loss of appetite or thirst, these conditions should be immediately reported to their health care provider. 
  * Patients should be instructed NOT to double the next dose if a dose is missed. The next dose should be taken at the usual time.